Efficacy of combination therapy with probiotics and mosapride in patients withIBSwithout diarrhea: a randomized, double‐blind, placebo‐controlled, multicenter, phase II trial

• DOI: 10.1111/nmo.12544
• Publication Date: 2015-03-25T07:29:44Z
• Authors: C. H. Choi; J. G. Kwon; S. K. Kim; S.‐J. Myung; K. S. Park; C.‐I. Sohn; P.‐L. Rhee; K. J. Lee; O. Y. Lee; H.‐K. Jung; S. R. Jee; Y. T. Jeen; M.‐G. Choi; S. C. Choi; K. C. Huh; H. Park
• Keywords: Mosapride

Abstract Background Probiotics can be beneficial in irritable bowel syndrome ( IBS ). Mosapride citrate, a selective 5‐ HT 4 receptor agonist, stimulates gastrointestinal motility. We investigated the efficacy of combination therapy with probiotics and mosapride for non‐diarrheal‐type . Methods Two hundred eighty‐five patients were randomly assigned to either Bacillus subtilis Streptococcus faecium ) at one four different doses or placebo weeks. The primary outcome was proportion experiencing adequate relief AR global symptoms week 4. secondary outcomes included subject's assessment SGA symptom relief, individual symptoms, stool parameters, ‐quality life. Key Results significantly higher all treatment groups compared group (53.7% 1, 55.0% 2, 55.2% 3, 53.6% [the highest dose], 35.1% group, respectively, p < 0.05). reporting ‘completely considerably relieved’ than group. abdominal pain/discomfort score more prominently improved that In constipation‐predominant , improvements frequency consistency those Conclusions & Inferences Combination is effective study has been registered US National Library Medicine http://www.clinicaltrials.gov NCT01505777).